Inflammasome ASC | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

7,394 results for “Inflammasome ASC”

ZyVersa Therapeutics to Present Kidney Disease Drug VAR 200 at JPM Healthcare Conference 2025

ZyVersa Highlights Data on Inflammasome Inhibition for Type 2 Diabetes Prevention

ZyVersa's IC 100 Shows Promise as Disease-Modifying Treatment for Parkinson's Disease

ZyVersa Therapeutics Initiates Phase 2a Trial for First-in-Class Diabetic Kidney Disease Treatment VAR 200

Novel NLRP3 Inflammasome Inhibitors Show Promise for Treating Multiple Inflammatory Diseases

Inflammasome Therapeutics' K8 Implant Shows Promise in Geographic Atrophy Trial

NEK7 Emerges as Promising Inflammasome Target Despite Novartis Study Raising Questions About Universal Requirement

Novartis Receives Patent for Novel NLRP3 Inflammasome Inhibitors with Potential for Multiple Inflammatory Diseases

Error parsing response

NLRP3 Inflammasome Inhibition May Prevent Melanoma Hyper-Progression During Immunotherapy

Page 1 of 353